OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.68
−0.07%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- $0.91
- Revenue estimate
- $1.6B
Latest reported
- Last report date
- Jul 31, 2026
- EPS actual
- $0.41
- EPS estimate
- $0.91
- Revenue actual
- $1.6B
- Revenue estimate
- $1.6B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -17.1%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 31, 2026 | $0.91 | $0.41 | Miss -54.95% | $1.6B |
| May 7, 2026 | $0.83 | $0.71 | Miss -14.46% | $1.5B |
| Feb 12, 2026 | $0.73 | $0.63 | Miss -13.70% | $1.5B |
| May 1, 2025 | $0.89 | $1.02 | Beat 14.61% | $1.5B |
| Feb 13, 2025 | $0.92 | $0.90 | Miss -2.17% | $1.6B |
| Oct 31, 2024 | $0.90 | $0.87 | Miss -3.33% | $1.6B |
| May 2, 2024 | $0.97 | $1.22 | Beat 25.77% | $1.6B |
| Feb 15, 2024 | $0.80 | $0.88 | Beat 10.00% | $1.6B |
| Nov 2, 2023 | $1.04 | $0.87 | Miss -16.35% | $1.5B |
| May 4, 2023 | $1.18 | $1.08 | Miss -8.71% | $1.5B |
| Feb 16, 2023 | $0.85 | $0.81 | Miss -5.15% | $1.5B |
| Nov 3, 2022 | $1.12 | $1.32 | Beat 17.86% | $1.5B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026